HSBC Holdings’s VYNE Therapeutics VYNE Stock Holding History

HSBC Holdings’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-230	Closed	-$26K	–	3161
2020 Q4	$26K	Buy	230 +48	+26%	+$6.03K	﹤0.01%	3006
2020 Q3	$21K	Buy	+182	New	+$21.2K	﹤0.01%	2696

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

HSBC Holdings's VYNE Position: Q1 2021 in Review

HSBC Holdings sold out of VYNE Therapeutics (VYNE) in Q1 2021, closing a stake of 230 shares — an estimated $26K sold.

HSBC Holdings first reported a position in VYNE in Q3 2020 and held it in 2 quarters. The position peaked at $26K in Q4 2020. 89 funds tracked by Wall St. Rank hold VYNE as of Q1 2021.

HSBC Holdings reported no remaining VYNE Therapeutics position as of Q1 2021 after selling out during the quarter.
HSBC Holdings sold 230 VYNE Therapeutics shares in Q1 2021, an estimated $26K.
HSBC Holdings first reported a position in VYNE Therapeutics in Q3 2020 and held it in 2 quarters.
HSBC Holdings's VYNE Therapeutics position peaked at $26K in Q4 2020.
89 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2021.

Based on HSBC Holdings's 13F filing for Q1 2021, filed 14 May 2021.